KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Cash & Equivalents (2018 - 2025)

ClearPoint Neuro's Cash & Equivalents history spans 13 years, with the latest figure at $38.2 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 77.17% year-over-year to $38.2 million; the TTM value through Sep 2025 reached $38.2 million, up 77.17%, while the annual FY2024 figure was $20.1 million, 13.14% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $38.2 million at ClearPoint Neuro, down from $41.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $64.9 million in Q1 2021 and bottomed at $12.4 million in Q1 2025.
  • The 5-year median for Cash & Equivalents is $27.6 million (2022), against an average of $34.5 million.
  • The largest annual shift saw Cash & Equivalents surged 293.12% in 2021 before it crashed 67.54% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $54.1 million in 2021, then plummeted by 48.96% to $27.6 million in 2022, then fell by 16.2% to $23.1 million in 2023, then fell by 13.14% to $20.1 million in 2024, then soared by 90.15% to $38.2 million in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Cash & Equivalents are $38.2 million (Q3 2025), $41.5 million (Q2 2025), and $12.4 million (Q1 2025).